News -

New Scientific Poster on iLite™ Insulin Assay Ready Cell line – Download it now!

Performance data and product characteristics for a new iLite™ Insulin Assay Ready Cell line responsive to insulin was presented in a scientific poster at the PEGS Boston 2016 Summit. Make sure you download it now!

Answering to identified market needs in diabetes and obesity research and drug discovery, the new cell line launched by Euro Diagnostica is designed to address the needs of pharmaceutical- and biotechnology companies for the quantification of drug potency, and detection of neutralizing antibodies (NAbs).

In this scientific poster Dr. Michael G. Tovey reports how assay-ready frozen iLite reporter gene cells eliminate the principal inconveniences of cell-based assays in general and provide the basis for the establishment of rapid, precise and highly specific assays for both the quantification of human insulin and neutralizing anti-insulin antibodies even in the presence of human serum.

It is also shown how the assay-ready frozen cells provide a means of quantifying insulin activity or neutralizing antibodies without the need for cell culture. A vial can simply be thawed and an assay can be carried out immediately.

Click to download the poster "Establishment of a Novel Reporter-Gene Assay for the Quantification of Insulin Activity and Anti-Insulin Neutralizing Antibodies".

Topics

  • Diseases

Categories

  • ilite cell-based assays

Contacts

Trine Österbye

VP Biopharma Solutions iLite Cell-based Assays +46 40 53 76 47

Related media

New Scientific Poster on iLite™ Insulin Assay Ready Cell line – Download it now!
  • New Scientific Poster on iLite™ Insulin Assay Ready Cell line – Download it now!
  • License: All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .pdf
Not downloadable

Related content

Euro Diagnostica merges with Biomonitor – enters the fields of theranostics and personalized medicine

Euro Diagnostica, a leader in diagnostic solutions for autoimmune diseases, has entered into a merger agreement with Biomonitor, a leading company in theranostics and personalized medicine. Biomonitor’s patented cell-based assay platform iLite™, based on reporter gene technology, can both monitor functional drug activity and detect neutralizing antibodies.

Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Euro Diagnostica AB announces the launch of the iLite ADCC Activity Assay product line and iLite anti-CD20 ADCC Activity Set. Using iLite ADCC Activity Assays, ADCC can be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be followed by Target cells for HER2, EGFR and membrane bound TNF-alpha.

The latest issue of the journal Gen highlights iLite™ reporter gene assays

An article on the characteristics and utility of Euro Diagnostica´s cell based assays, iLite™, was published in the latest issue of the journal Gen (Nov 1, 2015 (Vol. 35, No. 19)).

New research on cell-based reporter gene iLite™ assays

The 10th International Congress on Autoimmunity is taking place in Leipzig, Germany April 6-10. The event provides an opportunity to hear about the hot topics in autoimmunity and discuss the newest therapeutic techniques and diagnostic tools as well as the most up-to-date research. We are happy to announce that we will hold a presentation relating to the use of a cell-based reporter gene assay.

Announcing the launch of iLite™ VEGF Assay Ready Cells

The launch of iLite™ VEGF Assay Ready Cells marks the first iLite™ reporter gene assay for use within the immuno-oncology area. The cells have been genetically engineered to specifically detect VEGF activity, and can be used to measure the potency of VEGF inhibitor drugs, as well as neutralizing antibodies against such drugs in human serum.

Discover new iLite™ IL-23 Assay Ready Cells

We are happy to introduce the iLite™ IL-23 Assay Ready Cells offering significant benefits as compared to conventional IL-23 assays. Using the iLite™ IL-23 Assay Ready Cells, a rapid assay for the functional activity of IL-23, without cross-reactivity with IL-12, can easily be set-up. Results are obtained within 6 h.

Euro Diagnostica is now launching a TLR4 responsive cell line, strengthening the iLite™ Assay Ready Cell portfolio within inflammation.

Toll-like receptor 4 (TLR4) plays a fundamental role in the activation of the innate immune response, which is why drug development of TLR4 antagonists is a hot topic for treatment of inflammatory diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis and multiple sclerosis.

Related events

Coral Gables Symposium 2016 Immunogenicity and the patient: The Future is Your's

Event date 5 October 2016 – 7 October 2016

Location The Biltmore Hotel, Coral Gables, Miami, Florida

2016 PEGS - Protein Engineering Summit

Event date 25 April 2016 – 29 April 2016

Location Seaport World Trade Center, Boston